Company profile for Capsida

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of hig...
We are a biotechnology company creating a new class of targeted gene therapies for debilitating and life-threatening genetic disorders in both central nervous system (CNS) and non-CNS indications. Current gene therapy approaches have shown dramatic efficacy in several rare diseases but are hindered by imprecise targeting. The inability to selectively transduce specific cells and tissues effectively drives administration of higher doses and resulting safety liabilities. We are addressing these concerns with our proprietary adeno-associated virus (AAV) engineering platform that generates capsids optimized to target specific tissues and cells.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
1290 Rancho Conejo Blvd, Newbury Park, CA 91320
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.biospace.com/drug-development/capsida-reports-patient-death-in-gene-therapy-trial

BIOSPACE
11 Sep 2025

https://www.businesswire.com/news/home/20250611109903/en/Capsida-Receives-FDA-IND-Clearance-for-Its-IV-Administered-Gene-Therapy-for-Parkinsons-Disease-Associated-With-GBA-Mutations

BUSINESSWIRE
11 Jun 2025

https://www.businesswire.com/news/home/20250529358091/en/Capsida-Receives-FDA-Fast-Track-Designation-for-Its-Potential-First-in-Class-IV-Administered-Gene-Therapy-for-STXBP1-Developmental-and-Epileptic-Encephalopathy

BUSINESSWIRE
29 May 2025

https://www.businesswire.com/news/home/20250514208408/en/Capsida-Presents-New-GLP-Toxicology-Data-Supporting-Recent-FDA-IND-Clearance-of-Its-First-in-Class-IV-administered-Gene-Therapy-for-STXBP1-Developmental-and-Epileptic-Encephalopathy

BUSINESSWIRE
14 May 2025

https://www.businesswire.com/news/home/20250512366164/en/Capsida-Receives-FDA-IND-Clearance-for-Its-First-in-Class-IV-administered-Gene-Therapy-for-STXBP1-Developmental-and-Epileptic-Encephalopathy

BUSINESSWIRE
12 May 2025

https://www.businesswire.com/news/home/20250428763273/en/Capsida-to-Present-Progress-Updates-at-the-ASGCT-Annual-Meeting-Including-NHP-GLP-Toxicology-Study-Results-for-its-Potential-First-in-Class-STXBP1-Developmental-and-Epileptic-Encephalopathy-Program-CAP-002-STXBP1-DEE

BUSINESSWIRE
28 Apr 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty